Clinical evidence dossier
Basal insulin
HbA1c
Evidence signal
Authoritative evidence signal
strong
This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.
Evidence snapshot
- Authoritative support records
- 3
- Supporting studies available for review
- 3
- Randomized trials
- 3
- Reported effects
- 6
Clinical conclusion
Basal insulin has a small positive evidence signal for HbA1c, but the clinical interpretation is limited.
The conclusion and evidence-signal classification are distinct authoritative fields and are reproduced as published.
Observed effects
Observed study estimates; not a pooled treatment effect.
Between-group effect
Absolute change
0.75 to 0.75 percentage
Change from baseline
Mean difference
-1.5 to -1.5 %
Between-group effect
Mean difference
-0.19 to -0.05 %
Change from baseline
Mean difference
-2.62 to -1.21 mmol/mol
Evidence composition
- Non-randomized studies
- 0
- Other designs
- 0
- Unresolved designs
- 0
- Magnitude-eligible effects
- 6
Consistency
Authoritative consistency classification
mostly_consistent
- Positive
- 2
- No effect
- 1
- Mixed
- 0
- Negative
- 0
Population and applicability
Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 3 studies described adult participants.
This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.
View reported population descriptions
These descriptions are reported across the supporting studies; they are not a single synthesized population.
- Young Adult (19–39)
- Middle Aged (40-64)
- Male
- Female
- with T2 Diabetes
- Adults with type 2 diabetes.
- Patients currently using basal insulin therapy.
- Adults diagnosed with type 2 diabetes
- Patients managing diabetes with lifestyle interventions or insulin therapy
Limitations
- Evidence uses heterogeneous comparison contexts: active_comparator, placebo, usual_care.
- 1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.
- 1 study contains conflicting p-value and significance fields; those significance claims are suppressed.
Supporting evidence
Inspect the authoritative studies and omitted support records for this dossier.